How the SARS coronavirus causes disease: Host or organism?

Journal of Pathology

Volumn 208, Issue 2, 2006, Pages 142-151

  Lo, Anthony W I ^a   Tang, Nelson L S ^a   To, Ka Fai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemokines; Coronavirus; Cytokines; Pathogenesis; SARS

Indexed keywords

ALPHA CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA B ANTIGEN; INTERLEUKIN 18; INTERLEUKIN 8; LECTIN; NUCLEOCAPSID PROTEIN; VIRUS ENVELOPE PROTEIN;

ALLELE; AUTOIMMUNITY; CORONAVIRUS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HISTOPATHOLOGY; HUMAN; IMMUNOGENETICS; LUNG ALVEOLUS CELL; MOLECULAR MECHANICS; NONHUMAN; OPEN READING FRAME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS VIRULENCE;

ANIMALS; CARBOXYPEPTIDASES; CHEMOKINES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, NATURAL; IMMUNOGENETICS; LECTINS; LUNG; PEPTIDYL-DIPEPTIDASE A; RECEPTORS, VIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 31144440673     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1897     Document Type: Review

References (100)

1. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-1994.
2. Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S. Klenk HD, et al. SARS - beginning to understand a new virus. Nature Rev Microbiol 2003;1:209-218.
3. Hui DS, Sung JJ. Treatment of severe acute respiratory syndrome. Chest 2004;126:670-674.
4. Wong RS, Wu A, To KF, Lee N, Lam CW, Wong CK, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br Med J 2003;326:1358-1362.
5. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125: 1011-1017.
6. Chan HL, Leung WK, To KF, Chan PK, Lee N, Wu A, et al. Retrospective analysis of liver function derangement in severe acute respiratory syndrome. Am J Med 2004;116:566-567.
7. Wong WM, Ho JC, Ooi GC, Mok T, Chan J, Hung IF, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS. J Am Med Assoc 2003;290:2663-2665.
8. Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. Kidney Int 2005;67:698-705.
9. Farcas GA, Poutanen SM, Mazzulli T, Willey BM, Butany J, Asa SL, et al. Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus. J Infect Dis 2005;191:193-197.
10. Ding Y, He L, Zhang Q, Huang Z, Che X, Hou J, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004;203:622-630.
11. Liu W, Tang F, Fontanet A, Zhan L, Zhao QM, Zhang PH, et al. Long-term SARS coronavirus excretion from patient cohort, China. Emerg Infect Dis 2004;10:1841-1843.
12. Leung GM, Chung PH, Tsang T, Lim W, Chan SK, Chan P, et al. SARS-CoV antibody prevalence in all Hong Kong patient contacts. Emerg Infect Dis 2004;10:1653-1656.
13. Chiu WK, Cheung PC, Ng KL, Ip PL, Sugunan VK, Luk DC, et al. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. Pediatr Crit Care Med 2003;4:279-283.
14. Cheung OY, Chan JW, Ng CK, Koo CK. The spectrum of pathological changes in severe acute respiratory syndrome (SARS). Histopathology 2004;45:119-124.
15. Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol 2003;200:282-289.
16. Franks TJ, Chong PY, Chui P, Galvin JR, Lourens RM, Reid AH, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 2003;34:743-748.
17. Hsiao CH, Wu MZ, Hsieh SW, Chien LC, Hwang KC, Su IJ. Clinicopathology of severe acute respiratory syndrome: an autopsy case report. J Formos Med Assoc 2004;103:787-792.
18. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, Butany J. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol 2005;18:1-10.
19. Lang ZW, Zhang LJ, Zhang SJ, Meng X, Li JQ, Song CZ, et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology 2003;35:526-531.
20. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003;361:1773-1778.
21. Tse GM, To KF, Chan PK, Lo AW, Ng KC, Wu A, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004;57:260-265.
22. To KF, Tong JH, Chan PK, Au FW, Chim SS, Chan KC, et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. J Pathol 2004;202:157-163.
23. Chan WS, Wu C, Chow SC, Cheung T, To KF, Leung WK, et al. Coronaviral hypothetical and structural proteins were found in the intestinal surface enterocytes and pneumocytes of severe acute respiratory syndrome (SARS). Mod Pathol 2005;18:1432-1439.
24. Chong PY, Chui P, Ling AE, Franks TJ, Tai DY, Leo YS, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004;128:195-204.
25. Chow KC, Hsiao CH, Lin TY, Chen CL, Chiou SH. Detection of severe acute respiratory syndrome-associated coronavirus in pneumocytes of the lung. Am J Clin Pathol 2004;121:574-580.
26. Nakajima N, Asahi-Ozaki Y, Nagata N, Sato Y, Dizon F, Paladin FJ, et al. SARS coronavirus-infected cells in lung detected by new in situ hybridization technique. Jpn J Infect Dis 2003;56:139-141.
27. Shieh WJ, Hsiao CH, Paddock CD, Guarner J, Goldsmith CS, Tatti K, et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan. Hum Pathol 2005;36:303-309.
28. Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol 2005;62:1113-1117.
29. Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004;39:302-310.
30. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG, et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003;423:240.
31. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263-270.
32. Rowe T, Gao G, Hogan RJ, Crystal RG, Voss TG, Grant RL, et al. Macaque model for severe acute respiratory syndrome. J Virol 2004;78:11401-11404.
33. Qin C, Wang J, Wei Q, She M, Marasco WA, Jiang H, et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol 2005;206:251-259.
34. WHO. In Severe Acute Respiratory Syndrome (SARS). World Health Organization; 2004; http://www.who.int/csr/en/snrs/en
35. Martina BE, Haagmans BL, Kuiken T, Fouchier RA, Rimmelzwaan GF, Van Amerongen G, et al. Virology: SARS virus infection of cats and ferrets. Nature 2003;425:915.
36. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, Wong BH, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005;102:14040-14045.
37. Li W, Greenough TC, Moore MJ, Vasilieva N, Somasundaran M, Sullivan JL, et al. Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J Virol 2004;78:11429-11433.
38. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
39. Wong SK, Li W, Moore MJ, Choe H, Farzan M. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 2004;279:3197-3201.
40. Xiao X, Chakraborti S, Dimitrov AS, Gramatikoff K, Dimitrov DS. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun 2003;312:1159-1164.
41. Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun 2004;314:235-241.
42. Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004;319:1216-1221.
43. Moore MJ, Dorfman T, Li W, Wong SK, Li Y, Kuhn JH, et al. Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2. J Virol 2004;78:10628-10635.
44. Nie Y, Wang P, Shi X, Wang G, Chen J, Zheng A, et al. Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression. Biochem Biophys Res Commun 2004;321:994-1000.
45. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637.
46. Chan PK, To KF, Lo AW, Cheung JL, Chu I, Au FW, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol 2004;74:1-7.
47. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112-116.
48. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metabol 2004;15:167-169.
49. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Med 2005;11:875-879.
50. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005;102:7988-7993.
51. Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha le D, et al. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun 2004;323:1124-1129.
52. Chan KC, Tang NL, Hui DS, Chung GT, Wu AK, Chim SS, et al. Absence of association between angiotensin converting enzyme polymorphism and development of adult respiratory distress syndrome in patients with severe acute respiratory syndrome: a case control study. BMC Infect Dis 2005;5:26.
53. Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS, Chan KC, et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem 2004;50:1683-1686.
54. Yang ZY, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004;78:5642-5650.
55. Jeffers SA, Tusell SM, Gillim-Ross L, Hemmila EM, Achenbach JE, Babcock GJ, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004;101:15748-15753.
56. Gramberg T, Hofmann H, Moller P, Lalor PF, Marzi A, Geier M, et al. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 2005;340:224-236.
57. Marzi A, Gramberg T, Simmons G, Moller P, Rennekamp AJ, Krumbiegel M, et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 2004;78:12090-12095.
58. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells. Blood 2005;106:2366-2374.
59. van Kooyk Y, Geijtenbeek TB. DC-SIGN: escape mechanism for pathogens. Nature Rev Immunol 2003;3:697-709.
60. Chiu RW, Chim SS, Lo YM. Molecular epidemiology of SARS - from Amoy Gardens to Taiwan. N Engl J Med 2003;349:1875-1876.
61. Chinese SMEC. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004;303:1666-1669.
62. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, et al. The Genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-1404.
63. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003;300:1394-1399.
64. Tan YJ, Teng E, Shen S, Tan TH, Goh PY, Fielding BC, et al. A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis. J Virol 2004;78:6723-6734.
65. Fielding BC, Tan YJ, Shuo S, Tan TH, Ooi EE, Lim SG, et al. Characterization of a unique group-specific protein (U122) of the severe acute respiratory syndrome coronavirus. J Virol 2004;78:7311-7318.
66. Chow SC, Ho CY, Tam TT, Wu C, Cheung T, Chan PK, et al. Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. J Clin Pathol (in press).
67. Law PT, Wong CH, Au TC, Chuck CP, Kong SK, Chan PK, et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol 2005;86:1921-1930.
68. Shen S, Lin PS, Chao YC, Zhong A, Yang X, Lim SG, et al. The severe acute respiratory syndrome coronavirus 3a is a novel structural protein. Biochem Biophys Res Commun 2005;330:286-292.
69. Ito N, Mossel EC, Narayanan K, Popov VL, Huang C, Inoue T, et al. Severe acute respiratory syndrome coronavirus 3a protein is a viral structural protein. J Virol 2005;79:3182-3186.
70. Yu CJ, Chen YC, Hsiao CH, Kuo TC, Chang SC, Lu CY, et al. Identification of a novel protein 3a from severe acute respiratory syndrome coronavirus. FEBS Lett 2004;565:111-116.
71. Tan YJ, Tham PY, Chan DZ, Chou CF, Shen S, Fielding BC, et al. The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells. J Virol 2005;79:10083-10087.
72. Tan YJ, Fielding BC, Goh PY, Shen S, Tan TH, Lim SG, et al. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol 2004;78:14043-14047.
73. Bellingan GJ. The pulmonary physician in critical care * 6: the pathogenesis of ALI/ARDS. Thorax 2002;57:540-546.
74. Chollet-Martin S. Polymorphonuclear neutrophil activation during the acute respiratory distress syndrome. Intensive Care Med 2000;26:1575-1577.
75. To KF, Chan PK, Chan KF, Lee WK, Lam WY, Wong KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001;63:242-246.
76. Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997;111:1306-1321.
77. Lee N, Chan PK, Ip M, Wong E, Ho J, Ho C, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol (in press).
78. Yang YH, Huang YH, Chuang YH, Peng CM, Wang LC, Lin YT, et al. Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. J Med Virol 2005;77:1-7.
79. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2005;288:L3-L15.
80. Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense. J Clin Invest 2000;105:985-993.
81. Glass WG, Rosenberg HF, Murphy PM. Chemokine regulation of inflammation during acute viral infection. Curr Opin Allergy Clin Immunol 2003;3:467-473.
82. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.
83. Ward SE, Loutfy MR, Blatt LM, Siminovitch KA, Chen J, Hinek A, et al. Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. Antivir Ther 2005;10:263-275.
84. Jiang Y, Xu J, Zhou C, Wu Z, Zhong S, Liu J, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005;171:850-857.
85. Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 2005;75:185-194.
86. Tang NL, Chan PK, Wong CK, To KF, Wu A, Sung YM, et al. Early enhanced expression of IP-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome (SARS). Clin Chem 2005;51:2333-2340.
87. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 2004;173:4030-4039.
88. Agostini C, Facco M, Siviero M, Carollo D, Galvan S, Cattelan AM, et al. CXC chemokines IP-10 and mig expression and direct migration of pulmonary CD8+/CXCR3+ T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am J Respir Crit Care Med 2000;162:1466-1473.
89. Belperio JA, Keane MP, Burdick MD, Lynch JP 3rd, Zisman DA, Xue YY, et al. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol 2003;171:4844-4852.
90. Ng PC, Lam CW, Li AM, Wong CK, Leung TF, Cheng FW, et al. Chemokine response in children with SARS. Arch Dis Child 2005;90:422-423.
91. Marshall RP, Webb S, Hill MR, Humphries SE, Laurent GJ. Genetic polymorphisms associated with susceptibility and outcome in ARDS. Chest 2002;121:68S-69S.
92. Villar J, Flores C, Mendez-Alvarez S. Genetic susceptibility to acute lung injury. Crit Care Med 2003;31:S272-S275.
93. Menges T., Hermans PW, Little SG, Langefeld T, Boning O, Engel J, et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet 2001;357:1096-1097.
94. Marshall RP, Webb S, Bellingan GJ, Montgomery HE, Chaudhari B, McAnulty RJ, et al. Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002;166:646-650.
95. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002;30:969-973.
96. Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, Pison U, et al. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet 2000;58:181-191.
97. Takatsuka H, Takemoto Y, Mori A, Okamoto T, Kanamaru A, Kakishita E. Common features in the onset of ARDS after administration of granulocyte colony-stimulating factor. Chest 2002;121:1716-1720.
98. Itoyama S, Keicho N, Hijikata M, Quy T, Phi NC, Long HT, et al. Identification of an alternative 5′-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population. Am J Med Genet A 2005;136:52-57.
99. Lin M, Tseng HK, Trejaut JA, Lee HL, Loo JH, Chu CC, et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003;4:9.
100. Ng MH, Lau KM, Li L, Cheng SH, Chan WY, Hui PK, et al. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis 2004;190:515-518.